Results 141 to 150 of about 1,086 (210)

Current perspectives and challenges of using artificial intelligence in immunodeficiencies. [PDF]

J Allergy Clin Immunol
Rivière JG, Cantenys-Saba R, Carot-Sans G, Piera-Jiménez J, Butte MJ, Soler-Palacín P, Peng XP.   +6 more
europepmc   +1 more source

A Treat-to-Target approach in hereditary angioedema: expert consensus from a European committee. [PDF]

Front Immunol
Cancian M, Caballero T, Boccon-Gibod I, Buttgereit T, Cohn D, Eren E, Kiani-Alikhan S, Launay D, Mandelin J, Zanichelli A, Farkas H.   +10 more
europepmc   +1 more source

Molecular pharming—innovation, product development and manufacture

New Biotechnology, 2009
openaire   +1 more source

Ethical and Clinical Boundaries in Genomics & Newborn Screening: A Brief Report from IPIC2025. [PDF]

Int J Neonatal Screen
Yahyaoui R, Mamede L, Zach M, Taylor J, Booth C, Fisher R, Franková V, Ali A, Prevot J, Pergent M, Pena RA, Rivers E.   +11 more
europepmc   +1 more source

Management of hereditary angioedema with normal C1Inh: a series of 163 French patients. [PDF]

Orphanet J Rare Dis
Bocquet A, Bouillet L, Hardy G, Boccon-Gibod I, Deroux A, Arnaud M, Pelletier F, Thanh AD, Ozanne N, Armengol G, Jeandel PY, Sailler L, Taquet MC, Launay D, Fain O, Gobert D.   +15 more
europepmc   +1 more source

The ClinGen Severe Combined Immunodeficiency Disease Variant Curation Expert Panel: Specifications for classification of variants in ADA, DCLRE1C, IL2RG, IL7R, JAK3, RAG1, and RAG2. [PDF]

Genet Med
Jacovas VC, Zelnick M, McNulty S, Ross JE, Khurana N, Pan X, Nieto A, Martin S, McLean B, Elnagheeb MA, Cowan MJ, Puck JM, Hershfield MS, Verbsky J, Walter J, Allenspach EJ, Chan AY, van Oers NSC, Ghosh R, Piazza M, Yuan B, Notarangelo LD, Johnson BA, Chinn IK, Severe Combined Immunodeficiency Variant Curation Expert Panel.   +24 more
europepmc   +1 more source

Mast cell mediators in hereditary angioedema. [PDF]

Orphanet J Rare Dis
Horváth HR, Andrási N, Nagy E, Imreh É, Farkas H.   +4 more
europepmc   +1 more source

PAXIS: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Phase 2 Study (Part 1) Followed by an Open-Label Period (Part 2) to Assess the Efficacy and Safety of Pacritinib in Patients with VEXAS Syndrome. [PDF]

J Clin Med
Beck DB, Heiblig M, Savic S, Ferrada MA, Mekinian A, Chowdhury O, Hammond D, Weeks LD, Gurnari C, Kirino Y, Georgin-Lavialle S, Buckley SA, Garcha R, Harder BG, Koster MJ.   +14 more
europepmc   +1 more source

Sociodemographic drivers of care disparity among patients with inborn errors of immunity. [PDF]

Curr Opin Pediatr
Neary CM, Ong MS, Farmer JR.
europepmc   +1 more source

STAT6 gain-of-function disease: p.D519N is a new disease-causing variant that responds well to dupilumab treatment. [PDF]

J Allergy Clin Immunol Glob
Samra S, Cook E, Wilson J, Sharma M, Golding L, Yao DT, Marsh RA, Turvey SE.   +7 more
europepmc   +1 more source